Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timm Denecke

Showing results (271-280 of 284) with videos related to

Pageof 29
Sort By:
Annals of Surgical Oncology|March 16, 2020
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306Dominik Paul Modest, Volker Heinemann, Gunnar Folprecht, et al.
Transplantation and Cellular Therapy|July 18, 2025
Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed MyelomaThomas C Wiemers, Maximilian Ferle, Jonas Ader, et al.
Hemasphere|June 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myelomaPatrick Born, David Fandrei, Song Yau Wang, et al.
Journal of Neuroendocrinology|December 14, 2023
Use and perceived utility of [<sup>18</sup> F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.
Journal of Neuroendocrinology|December 9, 2024
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task ForceVikas Prasad, Anna Koumarianou, Timm Denecke, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|July 30, 2024
Generative Pre-trained Transformer 4 analysis of cardiovascular magnetic resonance reports in suspected myocarditis: A multicenter studyKenan Kaya, Carsten Gietzen, Robert Hahnfeldt, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|March 16, 2026
Artificial Intelligence in Radiology: Unlocking New Dimensions of ValueFabian Bamberg, Gerhard Adam, Gerald Antoch, et al.
Journal of Neuroendocrinology|November 26, 2024
Screening and surveillance practices for Multiple Endocrine Neoplasia type 1-related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire studyCarolina R C Pieterman, Simona Grozinsky-Glasberg, Dermot O'Toole, et al.
The Lancet. Oncology|July 3, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)Christophe M Deroose, Hannes Leupe, Rodney J Hicks, et al.
Pageof 29

Showing results (271-280 of 284) with videos related to

Sort By:
Pageof 29
Annals of Surgical Oncology|March 16, 2020
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306Dominik Paul Modest, Volker Heinemann, Gunnar Folprecht, et al.
Transplantation and Cellular Therapy|July 18, 2025
Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed MyelomaThomas C Wiemers, Maximilian Ferle, Jonas Ader, et al.
Hemasphere|June 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myelomaPatrick Born, David Fandrei, Song Yau Wang, et al.
Journal of Neuroendocrinology|December 14, 2023
Use and perceived utility of [<sup>18</sup> F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.
Journal of Neuroendocrinology|December 9, 2024
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task ForceVikas Prasad, Anna Koumarianou, Timm Denecke, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|July 30, 2024
Generative Pre-trained Transformer 4 analysis of cardiovascular magnetic resonance reports in suspected myocarditis: A multicenter studyKenan Kaya, Carsten Gietzen, Robert Hahnfeldt, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|March 16, 2026
Artificial Intelligence in Radiology: Unlocking New Dimensions of ValueFabian Bamberg, Gerhard Adam, Gerald Antoch, et al.
Journal of Neuroendocrinology|November 26, 2024
Screening and surveillance practices for Multiple Endocrine Neoplasia type 1-related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire studyCarolina R C Pieterman, Simona Grozinsky-Glasberg, Dermot O'Toole, et al.
The Lancet. Oncology|July 3, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)Christophe M Deroose, Hannes Leupe, Rodney J Hicks, et al.
Pageof 29